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Abstract   
Background: Hypercoagulability is a well-known feature of canine immune-mediated hemolytic 
anemia (IMHA) and is believed to increase the risk of thrombosis. This study was undertaken to 
differentiate the relative contribution of platelets and clotting proteases to this hypercoagulability 
using thromboelastography (TEG).  
Study design: Retrospective observational study.  
Methods: Thromboelastograms from 27 dogs with IMHA were retrospectively evaluated. 
Standard TEG parameters (R, K, α, MA), the G value and the novel parameter delta (Δ) were 
determined. Hypercoagulability was attributed to the platelet component of hemostasis when 
there was an increased G value with a normal Δ value. 
Key findings:  19 of 27 dogs (70.4%) had ≥ 2 TEG variables suggestive of hypercoagulability, 
18 (66.7%) had a hypercoagulable G value, and 11 (40.7%) had a hypercoagulable Δ value.  Ten 
of 27 (37%) samples met the criteria for platelet hypercoagulability.  
Significance: Our report documents the derivation and application of the Δ value to differentiate 
enzymatic from platelet hypercoagulability. Further studies are required to validate the use of 
these TEG variables in this manner. The hypercoagulable tendency in dogs with IMHA is 
complex and multifactorial and in some dogs this hypercoagulability may be attributed primarily 
to platelet hyper-reactivity. Our findings may support the use of anti-platelet drugs in some dogs 
with IMHA. 




α – alpha angle  
IMHA – immune mediated hemolytic anemia 
K- clot formation time 
MA- maximum amplitude 
R – reaction time 
SP – split point 
TEG – thromboelastography 





The hypercoagulable state in canine immune-mediated hemolytic anemia (IMHA) is an 
important cause of morbidity and mortality, resulting in an increased risk of thromboembolic 
disease.1 In general, hypercoagulability can be the result of increased platelet reactivity, 
increased clotting factor activity, or a combination of both.2 Despite the use of drugs to decrease 
clot formation, mortality in canine IMHA remains high (50-70%).3-5  This is possibly due to a 
lack of knowledge of the most appropriate pharmacologic intervention for treating the 
hypercoagulable state in individual dogs. 
Thromboelastography (TEG) is a viscoelastic test that is becoming more widely used in 
clinical veterinary practice. Unlike conventional plasma-based coagulation tests, TEG gives a 
global assessment of a patient’s coagulation status, and documents clot formation from initial 
platelet-fibrin interactions through fibrinolysis.6,7,18 
There are a number of standard measured values derived from the TEG tracings 
(thromboelastograms) that may be used to define the coagulation state of a patient [hypo- or 
hypercoagulable (Figure 1)].7-9 The reaction time (R) represents the time of latency from the 
point when the blood was placed in the TEG analyzer to the start of fibrin formation. The R 
value is most representative of the initial phase of clot formation by enzymatic clotting factors. 
The clot formation time (K), is the time after the R time necessary for the 2 arms of the 
thromboelastogram to diverge by 20 mm, and alpha (α) is the angle created by the tangent to the 
thromboelastogram. K and α both denote the speed of fibrin formation and cross-linking, and 
indicate cleavage of available fibrinogen into fibrin by thrombin generated in earlier reactions.  
Maximum amplitude (MA) is the maximal distance between the 2 divergent arms of the 
 
 
thromboelastogram; it is a direct function of the maximum dynamic properties of fibrin and 
platelet bonding and represents the ultimate strength of the clot.7   
A recent human report evaluated the use of non-conventional TEG parameters (G and Δ) 
to characterize the etiology of a hypercoagulable state as platelet or enzymatic in origin.10. The 
TEG Δ parameter is calculated from the difference between the R time and the split point (SP, 
min) of the TEG tracing (R-SP, Figure 1). The SP is the first point at which the arms of the 
thromboelastogram diverge.  The Δ value in people has a strong linear correlation with the time 
to maximum rate of thrombus generation (TMRTG, measured by the TEG and displayed as part 
of the thrombus velocity curve, Figure 1).10  TMRTG and other velocity curve parameters may 
be surrogate markers of thrombin generation.11  Thus, Δ may estimate thrombin generation and 
the enzymatic (clotting factor) contribution to clot formation.  The G value is a calculated 
measure of total clot strength (G= 5000 x MA/100 - MA) and represents both the enzymatic and 
platelet contribution to clot formation.8 By evaluating Δ and G, characterization of 
hypercoagulability as enzymatic or platelet in origin may be possible.10   
We hypothesized that the hypercoagulable state present in dogs with IMHA could be 
further characterized with respect to a platelet or enzymatic etiology using TEG. This study can 
provide the basis for further research into the etiologic characterization of hypercoagulability in 
dogs using TEG.  
 
 
Materials and Methods 
Retrospective analysis of TEG records from dogs with IMHA at the Queen Mother 
Hospital for Animals, the Royal Veterinary College, between July 2008 and August 2012 was 
performed.  The TEG database was searched for patients with a diagnosis of IMHA. Inclusion 
criteria were further defined to only include data from kaolin-activated TEG analyses. Several 
dogs had multiple TEG analyses performed during their hospitalization; only the first TEG 
analyzed from each case was included.  For inclusion in this study, a diagnosis of IMHA 
included anemia (PCV<30%), evidence of hemolysis (ie, hyperbilirubinemia, bilirubinuria, 
hemoglobinemia, hemoglobinuria, or spherocytosis), and 1 of the following: persistent auto-
agglutination, positive direct anti-globulin test (Coombs’ test), regenerative anemia with 
spherocytosis, or non-regenerative anemia with bone marrow cytology suggestive of IMHA.  
Additional information obtained from the clinical records included the sex, neutering 
status, age, weight and breed of each dog. Data was also gathered regarding PCV, medical 
treatments, and transfusions administered prior to blood collection for TEG analysis. 
Blood samples were collected by careful jugular venipuncture according to our 
institution’s standard operating procedures, using minimal stasis, a 21-Ga needle, and a syringe. 
Blood samples were immediately transferred into 1.3 mL, non-vacuum, polypropylene citrated 
tubesa  and inverted carefully to ensure mixing to a final concentration of 1 part 3.2% buffered 
trisodium citrate to 9 parts whole blood. After a 30-minute incubation at room temperature, 
citrated whole blood samples were activated with kaolin by aliquoting 1mL of citrated whole 
blood into manufacturer-supplied kaolin vialsb (containing kaolin, phospholipids and buffered 
stabilizers) and carefully inverted once. Immediately, 340μL of the sample was placed into a 
 
 
heparinase coated cupb with 20 μL of calcium chlorideb to initiate TEG analysis. The TEG 
analyses were performed on a single TEG machine,c by 1 of 4 operators, according to the 
manufacturer’s instructions.  Five TEG parameters were recorded from each thromboelastogram: 
R, K, α, SP, and MA. The G and Δ values were calculated by the investigators.  
Hypercoagulability in the current study was defined as Δ < 0.45 min, G > 10000 
dynes/cm2 , or when 2 or more of the standard TEG parameters (R, K, α, MA) were indicative of 
hypercoagulability (ie, shortened R or K, and increased α or MA).12 Reference intervals for all 
the standard parameters (R, K, α, MA) were based on our institutional reference interval (Table 
2), which was derived from 27 healthy dogs that had kaolin-activated TEG analysis performed in 
duplicate, with the data analyzed using Robust Box Cox methods.13,14 The upper limit of the G 
value calculated from the reference interval was 9400 dynes/cm2. Based on these findings we 
defined hypercoagulability as G > 10000 dynes/cm2. Similarly, Δ (R-SP) was calculated for our 
normal healthy controls and the normal interval was 0.45-2.8 min. Therefore we defined 
hypercoagulability as Δ < 0.45 min.   Hypercoagulability attributed to platelet hyperreactivity (ie, 
without a enzymatic contribution) was defined when G > 10000 dynes/cm2 and Δ ≥ 0.45  min.   
Data were inspected visually for assessment of data distribution. Frequency analysis of 
the number of cases considered hypercoagulable by each method of hypercoagulability was 
carried out. Non-normally distributed data were reported as the median value and the range. 
Results  
The search of our institution’s TEG database identified 158 samples from dogs screened 
for IMHA. This included kaolin activated and citrated native (unactivated) samples; for this 
study only kaolin activated samples (n=34) were included in our analysis. Thrombelastograms 
 
 
were further excluded from study because of failure to satisfy the inclusion criteria for a 
confirmed diagnosis of IMHA (n=2) and where repeat samples from the same dog were 
performed for serial TEG monitoring (n=5); in these cases, only the initial TEG trace was 
included in our analysis. The final analysis included TEG tracings from 27 dogs with IMHA. 
Hematologic assessment documented a regenerative anemia in 21/27 (77.8%) of the dogs 
with the remainder showing a non-regenerative anemia. The median PCV for the population at 
the time of TEG analysis was 16% (range 11-27%). On the basis of the clinical history, further 
investigations and diagnostic tests, a final diagnosis of primary (idiopathic) IMHA was given to 
22 (81.5%) of the dogs. Three (11.1%) of the dogs were found to have IMHA secondary to 
another cause including systemic lupus erythematosus or ehrlichia and 2 (7.4%) were not fully 
investigated to rule out other causes due to financial constraints or early euthanasia. 
The median age of the population was 6.9 years (range 1.6 - 11.3 years). The 
predominant breed was Cocker Spaniel (n=8) with the rest being 1 of each of 19 other breeds.  
Seventeen of 27 (63%) dogs were females (15 spayed, 2 intact) and 10 (37%) were males (8 
castrated 2 intact). At the time of blood sampling, 20 dogs (74%) had already received or were in 
the process of receiving a packed red blood cell transfusion. Additionally, 22 dogs had received 
some form of medical treatment prior to TEG sampling, including prednisolone/dexamethasone 
(n=18), azathioprine (n=9), aspirin (n=2), cyclosporine (n=1) or mycophenolate (n=1). 
Nineteen dogs (70.4%) had ≥ 2 standard TEG variables (R, K, α, MA) indicative of a 
hypercoagulable state, Eighteen (66.7%) had a hypercoagulable G value and 11 (40.7%) had a 
hypercoagulable Δ value. From the total number of samples, 10/27 dogs (37%) had a 
hypercoagulable G value with a normal Δ value. Of the 19 dogs defined as hypercoagulable via 
 
 
standard TEG parameters, 9 (47.3 %) had a normal Δ value.. A summary of TEG values obtained 
and the frequency of dogs classified as hypercoagulable with respect to the different methods of 
classification and reference intervals is shown in Tables 1 and 2.  
Discussion 
In this study we attempted to use TEG variables to ascertain the relative contribution of 
platelet and enzymatic proteases to the hypercoagulable state in dogs with IMHA. This approach 
was predicated on a retrospective report describing similar results in 10 critically ill human 
patients.10 A major limitation of this study is the lack of validation of the parameter Δ to 
differentiate platelet from enzymatic hypercoagulability in dogs. This report describes the 
existence and derivation of this novel variable so it may be investigated in future studies.  
Nineteen of the 27 dogs studied (70%) were determined to be hypercoagulable on the 
basis of evaluation of commonly used TEG variables (R, K, α, MA), which is consistent with 
previous TEG studies in dogs with IMHA.15,19 The nature of the hypercoagulability in 
approximately 50% of these dogs (37% of the total number of dogs studied) was ascribed to 
increased platelet function. 
This report demonstrates the contribution of platelet reactivity to hypercoagulability, as 
defined in people, in canine patients with IMHA. If confirmed, our results could be used to 
justify the use of anti-platelet therapies such as clopidogrel and aspirin in specific patients to 
reduce the risk for the development of a thrombotic event. Further studies are needed to establish 
if these methods can be used to identify specific hypercoagulable states and prevent 




Future studies that document the presence of thrombi (with advanced imaging, 
specialized hemostatic assays, or post-mortem examinations) in animals with concurrent TEG 
analysis will be beneficial to determine the in vivo significance of hypercoagulable TEG tracings. 
Preliminary studies in this vein are available in abstract form.16,17 In addition, a comparison of 
the incidence of thrombus formation in patients with platelet or enzymatic hypercoagulability 
would be beneficial by allowing us to evaluate the effect of targeted treatment for these factors 
with drugs such as heparins or anti-platelet drugs. 
 Consensus guidelines have recently been established for TEG analysis in veterinary 
patients.18 Our study follows these guidelines for sample collection, handling, assay activation, 
test protocol, and establishment of institutional reference intervals. However, lack of 
standardization of the methodology for TEG analysis among veterinary centers8,9,19 limits 
comparison of TEG results between institutions and hampers wider application of findings to 
populations of interest. These issues as well as the small number of patients used in many 
clinical studies present a challenge for the interpretation of TEG in veterinary patients. We 
recognize that these confounding factors are also important limitations of our report.  
Another limitation of the current report is the lack of contemporaneous data for 
fibrinogen, platelet count, prothrombin time, and activated partial thromboplastin time. 
Fibrinogen and platelet count contribute to the characteristics of the TEG tracing; in particular, 
fibrinogen has a large impact on the kinetics of clot formation. Newly published consensus 
guidelines recommend that fibrinogen and platelet count be reported in addition to TEG results.18 
At the time of sampling, prior to the release of the consensus guidelines, these criteria were not a 
standard screening test for IMHA at our institution, however, future prospective evaluations of  
should report these variables. In addition, other modalities of assessing platelet function, such as 
 
 
platelet aggregometry or flow cytometry, may lend additional data to support the use of the Δ 
value when evaluated alongside TEG.  
We attempted to minimize pre-analytical factors that are known to influence TEG 
analysis such as traumatic venipuncture, storage time, and temperature.20 However, we recognize 
that other pre-analytic factors such as concurrent medical therapy,21 blood transfusions, 
hematocrit,22 platelet count, and fibrinogen concentration may have influenced our results. A  
number of patients also received blood transfusions prior to TEG sampling. As our institution 
uses leukoreduced packed red blood cells as the standard blood product in dogs, the impact of 
procoagulant microparticles typically found in non-leukoreduced blood transfusions23 on TEG 
tracings is not believed to have been a factor in our study.   Future prospective studies based on 
this report should control for these pre-analytical factors. 
Our report describes initial findings that with further validation could be clinically 
applicable for optimizing use of thromboprophylaxis in dogs with IMHA.  Our report documents 
the existence, derivation and potential application of the Δ variable, and suggests that TEG could 
be a valuable tool in the clinical assessment of hypercoagulable canine IMHA patients, in that it 
may allow for differentiation of enzymatic from platelet hypercoagulability. Our findings suggest 
that the hypercoagulable state in 50% of hypercoagulable IMHA dogs can be attributed to 
platelet hyper-reactivity and, in theory, justify the use of anti-platelet drugs such as clopidogrel 
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Table 1: Frequency of hypercoagulability in 27 dogs with immune mediated hemolytic anemia 
by the different methods of TEG assessment of hypercoagulability 
Method of assessment of hypercoagulability 
No of patients 
hypercoagulable 
Percentage of patients 
hypercoagulable (%) 
≥ 2 of the standard TEG variables (R, K, α, MA) 
hypercoagulable 
19 70.4 
G value >10000 dynes/cm2 18 66.7 
Δ < 0.45 min 11 40.7 
Platelet hypercoagulability                                                                            
(G value >10000 dynes/cm2 & Δ ≥ 0.45 min) 
10 37.0 
Platelet hypercoagulability from patients deemed 
hypercoagulable by G value (n=18) 
10 55.6 
Platelet hypercoagulability from patients deemed 






Table 2: Results of thromboelastography in 27 dogs with immune-mediated hemolytic anemia 
TEG 
parameter 









No of patients 
hypercoagulable 
% of patients 
hypercoagulable  
R (min) 5.1 2.3 - 9.2 3-9.5 < 3 4 14.8 
K (min) 1.1 0.8 - 3.1 1.6 – 5.1 < 1.6 18 66.7 
α (so) 73.5 51.3 - 81.3  35.9 – 68.1  > 68.1 18 66.7 





4200 – 9400 
> 10000 18 66.7 
Δ (min) 0.6 0.1 - 1.9 0.45 – 2.8 <0.45 11 40.7 
 
*Institutional laboratory reference interval derived from 27 healthy dogs using the Robust Box-




Figure 1: Sample of a thrombus velocity curve (in grey) depicted over a standard 
thromboelastography (TEG) tracing, showing correlation of the Δ value with thrombus 
generation parameters (reprinted and adapted with permission from Elsevier).10 R = reaction 
time; K = clot formation time; αo = alpha angle; MA = maximum amplitude; TTG = total 
thrombus generation; MRTG = maximum rate of thrombus generation; TMRTG = time to 
maximum rate of thrombus generation; R = reaction time; SP = split point; Δ = delta.  
 
